MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
16.73
-0.05 (-0.30%)
Nov 21, 2024, 1:20 PM EST - Market open
Company Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally.
It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.
MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd.
| Country | Israel |
| Founded | 2000 |
| IPO Date | Mar 20, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Ofer Gonen |
Contact Details
Address: 42 Hayarkon Street Yavne, 8122745 Israel | |
| Phone | 972 7 797 14100 |
| Website | mediwound.com |
Stock Details
| Ticker Symbol | MDWD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001593984 |
| CUSIP Number | M68830104 |
| ISIN Number | IL0011316309 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Ofer Gonen B.Sc. | Chief Executive Officer |
| Hani Luxenburg | Chief Financial Officer |
| Yaron Meyer Adv. | Executive Vice President, General Counsel and Corporate Secretary |
| Dr. Ety Klinger MBA, Ph.D. | Chief Research and Development Officer |
| Dr. Lior Rosenberg M.D. | Co-Founder |
| Dr. Shmulik Hess Ph.D. | Chief Operating Officer and Chief Commercial Officer |
| Dr. Liron Gal | Executive Director of Manufacturing Science and Technology |
| Barry J. Wolfenson | Executive Vice President of Strategy and Corporate Development |
| Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 6-K | Report of foreign issuer |
| Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 9, 2024 | EFFECT | Notice of Effectiveness |
| Sep 9, 2024 | 424B3 | Prospectus |
| Sep 5, 2024 | UPLOAD | Filing |
| Aug 29, 2024 | F-3 | Filing |
| Aug 15, 2024 | 6-K | Report of foreign issuer |
| Aug 14, 2024 | 6-K | Report of foreign issuer |